VEGFA and colorectal carcinoma: Notably, bevacizumab, a drug commonly used in clinical practice for CRC treatment, specifically binds to vascular endothelial growth factor, blocking its interaction with vascular endothelial growth factor receptor and subsequently inhibiting the signaling pathway of angiogenesis.